On March 19, 2026, the Honorable Denise Cote of the United States District Court for the Southern District of New York granted final approval of the Settlement reached on behalf of investors in In re Applied Therapeutics Securities Litigation, No. 1:24-cv-09715. The settlement provides for a settlement fund of $15 million in cash plus Warrant Proceeds (as described in the Stipulation of Settlement) of $17,000. The Settlement resolves claims that the Company misled investors regarding its 2024 New Drug Application for the drug candidate Govorestat. The Order also finally certified the Class and appointed Wolf Popper LLP serves as Court-appointed Class Counsel for the class.
In the Order approving the settlement, Judge Cote found that the agreement “in all respects, fair, reasonable, and adequate and in the best interest of the Class.” The class consists of investors who purchased Applied Therapeutics common stock on U.S. exchanges between January 3, 2024 and December 2, 2024.
Class members must submit a timely and valid claim form on or before April 8, 2026 in order to be eligible for a share of the net settlement fund.
More information about the settlement, as well as copies of the Longform Notice and Claim Form, can be found at the Settlement Website, www.apltsecuritiessettlement.com.